Current diagnostic guidelines for TA-TMA
Category . | Blood and Marrow Transplant Clinical Trials Network18 . | International Working Group of the European Group for Blood and Marrow Transplantation58 . | Probable TMA as defined by validation study by Cho et al53 . |
---|---|---|---|
Schistocytes | ≥ 2 per high-power field in peripheral blood | > 4% in peripheral blood | ≥ 2 per high-power field in peripheral blood |
LDH | Increased above institutional baseline | Sudden and persistent increase | Increased |
Renal function | Doubling of serum creatinine or 50% decrease in creatinine clearance from baseline before transplantation | ||
Platelets | Thrombocytopenia: < 50 × 109/L or a ≥ 50% decrease in platelet count | Thrombocytopenia: < 50 × 109/L or a ≥ 50% decrease in platelet count | |
Red cells | Decreased hemoglobin or increased red blood cell transfusions | Decreased hemoglobin | |
CNS | Unexplained neurologic dysfunction | ||
Coombs test | Negative direct and indirect | Negative | |
Haptoglobin | Decreased | Decreased | |
Other | No coagulopathy |
Category . | Blood and Marrow Transplant Clinical Trials Network18 . | International Working Group of the European Group for Blood and Marrow Transplantation58 . | Probable TMA as defined by validation study by Cho et al53 . |
---|---|---|---|
Schistocytes | ≥ 2 per high-power field in peripheral blood | > 4% in peripheral blood | ≥ 2 per high-power field in peripheral blood |
LDH | Increased above institutional baseline | Sudden and persistent increase | Increased |
Renal function | Doubling of serum creatinine or 50% decrease in creatinine clearance from baseline before transplantation | ||
Platelets | Thrombocytopenia: < 50 × 109/L or a ≥ 50% decrease in platelet count | Thrombocytopenia: < 50 × 109/L or a ≥ 50% decrease in platelet count | |
Red cells | Decreased hemoglobin or increased red blood cell transfusions | Decreased hemoglobin | |
CNS | Unexplained neurologic dysfunction | ||
Coombs test | Negative direct and indirect | Negative | |
Haptoglobin | Decreased | Decreased | |
Other | No coagulopathy |
Reprinted by permission from Wolters Kluwer Health.53